Russian scientists working on fast-acting Ebola vaccine

Russian scientists are developing a technology to make monoclonal antibodies specific to the Ebola virus. If successful, the resulting medicine could be available as soon as December. Testing points to a positive effect within 24 hours of administering. Mikrogen – one of the Russian leaders in the market for alternatives to antibiotics first had the idea. The company partnered up with the health ministry in Ufa, in Russia’s Republic of Bashkortostan, to develop “a system for rapidly diagnosing the virus in human fluids and in the environment.” If trials are successful, the company plans to use the lessons to develop medication based off of custom-made recombinant antibodies. They say it would have almost immediate effect on the condition of the patient and that given the green light the treatment could be ready for mass production within two months. “The use of specific recombinant antibodies is, for the time being, the most promising approach...